A novel study emerging from the University of Sydney has illuminated the promising role of melatonin, a widely available sleep aid traditionally employed to counter insomnia, in mitigating chronic musculoskeletal pain. This revelation, published in the esteemed journal PAIN, could significantly reduce dependency on conventional analgesics, including opioids and non-steroidal anti-inflammatory drugs (NSAIDs), thereby potentially revolutionizing chronic pain management worldwide.
Chronic musculoskeletal pain afflicts nearly half the global population, underscoring an urgent need for affordable, safe, and accessible therapeutic alternatives. The University of Sydney’s research, a robust systematic review and meta-analysis encompassing data from over two thousand participants across 23 randomized controlled trials, reveals that melatonin’s analgesic effects rival those of established pain medications. This unexpected finding offers an innovative pathway in pain therapeutics, emphasizing repurposing existing drugs to address pervasive health challenges.
Melatonin, a hormone intricately tied to regulating circadian rhythms and sleep cycles, is already ubiquitously present in household medicine cabinets. What makes this hormone particularly intriguing is its dual function beyond sleep regulation — the ability to exert analgesic properties that alleviate chronic pain symptoms. This characteristic positions melatonin not only as a sleep enhancer but also as a multifaceted therapeutic agent capable of addressing the intertwined nature of pain and sleep disturbances often observed in chronic pain sufferers.
The collaborative research effort, spearheaded by Kangchao Wu from Sydney’s Musculoskeletal Research Hub, meticulously synthesized findings from diverse populations hailing from countries including the United States, Russia, Brazil, Egypt, and China. Participants were varied, ranging from those suffering from prevalent conditions such as low back pain, osteoarthritis, and fibromyalgia to individuals undergoing recovery from orthopedic surgeries such as joint replacements and spinal procedures. This diversity enhances the study’s external validity, suggesting melatonin’s widespread applicability.
Quantitatively, melatonin demonstrated a consistent reduction in pain scores by approximately nine points on a standardized 0–100 scale, with the highest-caliber trials reporting pain relief nearing ten points. This magnitude aligns closely with reductions achieved via opioids and NSAIDs, illustrating melatonin’s potential as a comparable analgesic. Furthermore, the supplement improved sleep quality, reinforcing the well-documented bidirectional relationship between sleep disruptions and heightened pain sensitivity, and implying that melatonin’s benefits are twofold.
Intriguingly, the study delved into dosage nuances, documenting variations from as low as one milligram to as high as ten milligrams of melatonin depending on the clinical setting. Chronic musculoskeletal pain management most commonly employed doses around three milligrams per day, typically administered at bedtime or shortly before sleep initiation, while postoperative pain protocols often utilized slightly higher doses ranging from five to six milligrams. The absence of a definitive dose-response curve in the current evidence marks an area ripe for further investigation, indicating that optimal dosing strategies remain to be precisely established.
Safety profiles emerged as a crucial element in favoring melatonin as a pain management adjunct. Adverse effects such as nausea, dizziness, and headaches were reported but occurred at rates comparable to placebo groups, with no serious adverse events documented. The hormone’s tolerability and lack of dependence potential distinguish it significantly from opioids, whose long-term use carries well-known risk profiles including addiction and severe organ toxicity, thereby spotlighting melatonin’s clinical attractiveness.
Although melatonin enjoys widespread availability in many countries as an over-the-counter supplement, its regulation is notably more stringent in jurisdictions like Australia. Here, melatonin primarily requires a prescription, except for low-dose formulations (two milligrams or less), which pharmacists can dispense without prescription for short-term insomnia treatment in adults aged 55 and above. This regulatory landscape necessitates patient-doctor consultations to ensure safety, particularly when melatonin is incorporated into comprehensive pain treatment regimens involving polypharmacy or patients with comorbidities.
The findings underscore melatonin’s potential incorporation as an adjunctive therapy rather than a wholesale replacement for existing pain medications, particularly in individuals experiencing concomitant sleep disturbances. This nuanced approach reflects the complex interplay between pain and sleep, advocating for integrative treatment models that target both symptoms concurrently to enhance patient outcomes and quality of life.
This study exemplifies the promising paradigm of drug repurposing, wherein established therapeutics are redirected towards novel applications to expedite medical advances. Such strategies circumvent the lengthy and costly drug development process, offering immediate translational potential backed by existing safety data. Melatonin’s repositioning for musculoskeletal pain exemplifies this trend, carving a faster route from bench to bedside in addressing a global health burden.
The researchers caution that while current evidence is compelling, larger-scale, high-quality clinical trials are imperative to refine dosage optimization, long-term efficacy, and safety profiles across heterogeneous patient populations. Nonetheless, the existing data establishes a strong foundation for cautious, evidence-informed integration of melatonin into multidisciplinary pain management protocols.
In a context increasingly dominated by concerns over opioid overuse and associated public health crises, the identification of melatonin as a viable, safer analgesic alternative offers a beacon of hope for both clinicians and patients. Its dual efficacy in pain reduction and sleep enhancement positions melatonin uniquely, fostering a more holistic approach in chronic musculoskeletal pain care.
In conclusion, melatonin’s repositioning from a sleep aid supplement to a potent modulator of chronic musculoskeletal pain signifies a breakthrough in managing one of the most pervasive health challenges globally. Its cost-effectiveness, safety, and accessibility render it a prime candidate to complement existing pharmacotherapies, reducing side effect burdens and improving patient quality of life across diverse clinical settings.
Subject of Research: People
Article Title: Efficacy and effectiveness of melatonin for the management of musculoskeletal pain: a systematic review and meta-analysis of placebo and active controlled trials
News Publication Date: 30-Jun-2026
Web References: DOI 10.1097/j.pain.0000000000004045
References: Published in PAIN; systematic review of 23 randomized controlled trials involving 2028 adults
Keywords: Melatonin, Chronic pain, Fibromyalgia, Pain, Musculoskeletal system, Sleep, Insomnia, Analgesics, Opioids, Back pain, Osteoarthritis, Public health
Tags: affordable chronic pain therapieschronic musculoskeletal pain treatmentcircadian rhythm and pain modulationmelatonin analgesic effectsmelatonin for chronic pain reliefmelatonin hormone therapeutic usesmelatonin vs NSAIDs effectivenessmeta-analysis on melatonin pain reliefnon-opioid pain management alternativesopioid-sparing pain treatmentsrepurposing sleep aids for painUniversity of Sydney pain study
